1. Home
  2. NAMSW vs MANH Comparison

NAMSW vs MANH Comparison

Compare NAMSW & MANH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • NAMSW
  • MANH
  • Stock Information
  • Founded
  • NAMSW N/A
  • MANH 1990
  • Country
  • NAMSW Netherlands
  • MANH United States
  • Employees
  • NAMSW 29
  • MANH N/A
  • Industry
  • NAMSW Biotechnology: Pharmaceutical Preparations
  • MANH Computer Software: Prepackaged Software
  • Sector
  • NAMSW Health Care
  • MANH Technology
  • Exchange
  • NAMSW Nasdaq
  • MANH Nasdaq
  • Market Cap
  • NAMSW N/A
  • MANH N/A
  • IPO Year
  • NAMSW N/A
  • MANH 1998
  • Fundamental
  • Price
  • NAMSW $9.00
  • MANH $218.59
  • Analyst Decision
  • NAMSW
  • MANH Strong Buy
  • Analyst Count
  • NAMSW 0
  • MANH 7
  • Target Price
  • NAMSW N/A
  • MANH $248.86
  • AVG Volume (30 Days)
  • NAMSW N/A
  • MANH 500.8K
  • Earning Date
  • NAMSW N/A
  • MANH 07-23-2024
  • Dividend Yield
  • NAMSW N/A
  • MANH N/A
  • EPS Growth
  • NAMSW N/A
  • MANH 39.91
  • EPS
  • NAMSW N/A
  • MANH 3.05
  • Revenue
  • NAMSW N/A
  • MANH $962,264,000.00
  • Revenue This Year
  • NAMSW N/A
  • MANH $13.27
  • Revenue Next Year
  • NAMSW N/A
  • MANH $11.60
  • P/E Ratio
  • NAMSW N/A
  • MANH $71.36
  • Revenue Growth
  • NAMSW N/A
  • MANH 18.92
  • 52 Week Low
  • NAMSW N/A
  • MANH $182.97
  • 52 Week High
  • NAMSW N/A
  • MANH $266.94
  • Technical
  • Relative Strength Index (RSI)
  • NAMSW 47.49
  • MANH 32.17
  • Support Level
  • NAMSW $9.40
  • MANH $215.62
  • Resistance Level
  • NAMSW $10.14
  • MANH $245.00
  • Average True Range (ATR)
  • NAMSW 0.44
  • MANH 6.18
  • MACD
  • NAMSW -0.12
  • MANH -3.73
  • Stochastic Oscillator
  • NAMSW 24.31
  • MANH 8.51

About NAMSW NewAmsterdam Pharma Company N.V. Warrant

NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments.

Share on Social Networks: